Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study

被引：0

作者：

Moreau, Philippe ^{[1
]}

Facon, Thierry ^{[2
]}

Usmani, Saad ^{[3
]}

Kumar, Shaji ^{[4
]}

Plesner, Torben ^{[5
,6
]}

Goldschmidt, Hartmut ^{[7
,8
]}

Orlowski, Robert ^{[9
]}

Perrot, Aurore ^{[10
]}

Chari, Ajai ^{[11
]}

Cook, Gordon ^{[12
]}

Pei, Huiling ^{[13
]}

Van Rampelbergh, Rian ^{[14
]}

Bartlett, J. Blake ^{[15
]}

Uhlar, Clarissa ^{[16
]}

Carson, Robin ^{[16
]}

Bahlis, Nizar ^{[17
]}

机构：

[1] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[2] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[3] Mem Sloan Kettering Canc Ctr, New York, NY USA

[4] Mayo Clin Rochester, Dept Hematol, Rochester, MN USA

[5] Vejle Hosp, Vejle, Denmark

[6] Univ Southern Denmark, Vejle, Denmark

[7] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany

[8] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[9] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[10] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[11] Icahn Sch Med Mt Sinai, New York, NY USA

[12] Leeds Inst Clin Trials Res, Leeds Canc Res UK CTU, Leeds, W Yorkshire, England

[13] Janssen Res & Dev LLC, Titusville, NJ USA

[14] Janssen Res & Dev, Beerse, Belgium

[15] Janssen Res & Dev LLC, Raritan, NJ USA

[16] Janssen Res & Dev LLC, Spring House, PA USA

[17] Univ Calgary, Calgary, AB, Canada

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-039

引用

页码：S23 / S24

页数：2

共 50 条

[21] Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study
Kumar, Shaji K.
Facon, Thierry
Usmani, Saad Z.
Plesner, Torben
Orlowski, Robert Z.
Touzeau, Cyrille
Basu, Supratik
Bahlis, Nizar J.
Goldschmidt, Hartmut
O'Dwyer, Michael E.
Venner, Christopher P.
Weisel, Katja
Hulin, Cyrille
Karlin, Lionel
Preis, Meir
Broyl, Annemiek
Renwick, William
Hansson, Markus
Krevvata, Maria
Wang, Jianping
Van Rampelbergh, Rian
Ukropec, Jon
Uhlar, Clarissa M.
Kobos, Rachel
Perrot, Aurore
BLOOD, 2020, 136
[22] Incidence of herpes zoster in transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone
Horigome, Yuichi
Kamata, Hirotoshi
Michishita, Yusuke
Yokoyama, Maki
Tadera, Noriyuki
Hayama, Kei
Suzuki, Takahiro
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025,
[23] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
Kumar, Shaji K.
Moreau, Philippe
Bahlis, Nizar Jacques
Facon, Thierry
Plesner, Torben
Orlowski, Robert Z.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Usmani, Saad
BLOOD, 2022, 140 : 10150 - 10153
[24] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study
Kumar, S. K.
Moreau, P.
Bahlis, N.
Facon, T.
Plesner, T.
Orlowski, R. Z.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Raje, N.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Wang, G.
Krevvata, M.
Carson, R.
Borgsten, F.
Usmani, S. Z.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 183 - 184
[25] Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)
Orlowski, Robert
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher
Weisel, Katja
Mace, Joseph
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Ahmadi, Tahamtan
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa
Tromp, Brenda
Delioukina, Maria
Vermeulen, Jessica
Usmani, Saad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S424 - S425
[26] Treatment Options for Newly Diagnosed Frail and Transplant-Ineligible Patients with Multiple Myeloma: A Systematic Review
Abdullah, Syed Maaz
Faisal, Muhammad Salman
Din, Mohammad Ammad Ud
George, Laeth L.
Khurshid, Qasim
Dar, Abdul Jabbar
Neupane, Karun
Ehsan, Amrat
Zaidi, Abdul Rehman Z.
Waris, Imtisaal
Haider, Mobeen Zaka
Setarehaseman, Alireza
Ahmad, Naqib
Babar, Arsalan
Ehsan, Hamid
Anwer, Faiz
BLOOD, 2020, 136
[27] Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
Perrot, Aurore
Facon, Thierry
Plesner, Torben
Usmani, Saad
Kumar, Shaji K.
Bahlis, Nizar Jacques
Hulin, Cyrille
Orlowski, Robert Z.
Nahi, Hareth
Mollee, Peter
Ramasamy, Karthik
Roussel, Murielle
Jaccard, Arnaud
Delforge, Michel
Karlin, Lionel
Arnulf, Bertrand
Chari, Ajai
Pei, Huiling
Gupta, Niodita
Kaila, Shuchita
Matt, Kathryn
Gries, Katharine S.
Carson, Robin
Borgsten, Fredrik
Weisel, Katja
BLOOD, 2022, 140 : 1142 - 1145
[28] Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone
Vogl, Dan T.
Delforge, Michel
Song, Kevin
Guo, Shien
Gibson, Craig J.
Ervin-Haynese, Annette
Facon, Thierry
LEUKEMIA & LYMPHOMA, 2018, 59 (02) : 398 - 405
[29] Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes
Perrot, Aurore
Facon, Thierry
Plesner, Torben
Usmani, Saad Z.
Kumar, Shaji
Bahlis, Nizar J.
Hulin, Cyrille
Orlowski, Robert Z.
Nahi, Hareth
Mollee, Peter
Ramasamy, Karthik
Roussel, Murielle
Jaccard, Arnaud
Delforge, Michel
Karlin, Lionel
Arnulf, Bertrand
Chari, Ajai
Wang, George
Gupta-Werner, Niodita
Kaila, Shuchita
Pei, Huiling
Matt, Kathryn
Gries, Katharine S.
Carson, Robin
Borgsten, Fredrik
Weisel, Katja
EUROPEAN JOURNAL OF HAEMATOLOGY, 2025,
[30] Impact on efficacy of the dose and schedule of bortezomib in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Ibarra, Gladys
Abril, Laura
Pena, Marta
Oriol, Albert
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E235 - E235

← 1 2 3 4 5 →